Topouzis Stavros

Director, Postgraduate Studies Program “Drug Discovery & Development”

Studies

1985: Bachelor of Pharmacy, Aristotelian University of Thessaloniki, Greece
1986: Diplôme d' 'Etudes Approfondies (DEA) de Pharmacologie et Pharmacochimie, Université Louis Pasteur I, Strasbourg, France.
1989: Doctorat de Pharmacologie Moléculaire et Cellulaire, Université Louis Pasteur I, Strasbourg, France.

Positions

• 1985-1990 Lab.de Pharmacol. Moleculaire et Cellulaire, Faculte de Pharmacie, U. Louis Pasteur and Merrel-Dow Research Institute, Strasbourg, FRANCE
  Doctoral student / Researcher
  Biology of Nitric Oxide and Endothelin, Molecular Mechanisms of Arterial Contractility
• 1990-1992 Dept. of Pharmacology/Toxicology, Medical College of GA, Augusta, Georgia USA
  Research Fellow and Graduate School Lecturer
  Endothelial and Vascular Smooth Muscle cell Biology, ACE activity in the vessel wall
• 1992-1998 Dept. of Pathology, Baylor College of Medicine, Houston, Texas, USA
  Research Associate (Junior Faculty)
  Vascular Wall Morphogenesis, Smooth Muscle Cell Lineage Diversity, TGF-β biology
• 1998-1999 Cell Biology/Discovery, MetaMorphix, Inc., Baltimore, Maryland USA
  Research Scientist
  Myostatin (GDF-8) biology, Skeletal Muscle growth and Glucose homeostasis
• 1999-2006 Discovery Biology, ZymoGenetics Inc., Seattle, Washington, USA
  Senior Scientist / Project Leader
  Protein-based Therapeutics for Cancer, Vascular and Immune Diseases, and Regenerative Medicine
• 2006- 2022 Molecular Pharmacology, Dept. of Pharmacy Univeristy of Patras, Patras, GREECE
  Current position: Associate Professor of Pharmacology and Toxicology
  Research in Vascular, Inflammatory and Fibroproliferative diseases
• 2022- now Molecular Pharmacology, Dept. of Pharmacy Univeristy of Patras, Patras, GREECE
  Current position: Professor of Pharmacology and Toxicology
  Research in Vascular, Inflammatory and Fibroproliferative diseases
•  

Teaching Activity

Undergraduate Program

• Physiology I [PHA-A25-NEW]
• Physiology II [PHA-B14-NEW]
• Pharmacology I [PHA-C13-NEW]
• Pharmacology II [PHA-C24-NEW]
• Toxicology [PHA-D24-NEW]
• Pharmaceutical Practice [PHA-E13-NEW]
• Pharmaceutical Care [PHA-E22-NEW]

Postgraduate Program “Drug Design and Development”

• Preclinical and Clinical Drug Evaluation [DPHA_4]
• Molecular Targets of Drug Action [DPHA_C01]
• Precision Therapeutics [DPHA_C03]

Interdepartmental Postgraduate Program “Informatics for Life Sciences”

• Basic Principles of Pathophysiology and Therapeutics [LSI 102]
• Complementary skills [LSI 303]

Interdepartmental Postgraduate Program "Personalized Medicine”

• Molecular Diagnostics - Biomarkers [ΕΙ 103]

Research Activities

Pharmacology of Vascular, Inflammatory and Fibroproliferative diseases

• Past and present investigations address the molecular pathways operating in endothelial and smooth muscle cells and which are amenable to targeting by novel or optimized therapeutics.
• These pathways control blood pressure and vascular resistance, inflammatory and thrombotic processes, solid tumor/wound angiogenesis, and are critically involved in the onset and progress of chronic cardiovascular and metabolic diseases (e.g. atherosclerosis, arterial calcification, restenosis).
• At the cellular and molecular levels, past research has addressed a) critical aspects of phenotypic determination and functional control of vascular smooth muscle and endothelial cells, triggered by morphogenetic cues (e.g. TGF-β and PDGF) and transcriptional regulators (e,g, SRF, Myocardins, COUP-TF II), and b) modulation of the interaction of the blood vessel wall with circulating cells such as monocytes/macrophages, platelets and T-cells (e.g. IL-22Rα2, TFPI-2, CNP, IL-31).

Patents

• United States Patent 7,172,757 February 6, 2007 Method of treating fibroproliferative disorders Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA), Gilbertson; Debra G. (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
• United States Patent 7,045,498 May 16, 2006 Soluble Zcytor11 cytokine receptors Inventors: Kindsvogel; Wayne R. (Seattle, WA); Topouzis; Stavros (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
• United States Patent 6,827,938 December 7, 2004 Compositions and methods for improving kidney function Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
• United States Patent 6,630,142 October 7, 2003 Method of treating fibroproliferative disorders Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA), Gilbertson; Debra G. (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
• United States Patent 6,368,597 April 9, 2002 Methods of treating diabetes Inventors: Strassmann; Gideon (Washington, DC), Liang; Li-fang (Elkridge, MD); Topouzis; Stavros (Elkridge, MD Assignee: MetaMorphix, Inc. (Baltimore, MD)

Listed as Inventor in >13 Published Patent Applications